ABCBI (MDRI)-Type P-Glycoproteins at the Blood-Brain Barrier Modulate the Activity of the Hypothalamic-Pituitary-Adrenocortical System: Implications for Affective Disorder

Neuropsychopharmacology

Volumn 28, Issue 11, 2003, Pages 1991-1999

  Müller, Marianne B ^a   Keck, Martin E ^a   Binder, Elisabeth B ^a   Kresse, Adelheid E ^a,b   Hagemeyer, Thomas P ^a   Landgraf, Rainer ^a   Holsboer, Florian ^a   Uhr, Manfred ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF GRAZ   (Austria)

Author keywords

Affective disorder; Blood brain barrier; Glucocorticoid; HPA system; MDR gene; Mouse

Indexed keywords

DEXAMETHASONE; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1;

ABCB1 GENE; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN PROTECTION; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICOSTERONE BLOOD LEVEL; DNA POLYMORPHISM; DOSE RESPONSE; GENE; GENE ACTIVITY; GENE FUNCTION; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IN VIVO STUDY; MALE; MOOD DISORDER; MOUSE; MULTIDRUG RESISTANCE; NEUROENDOCRINE SYSTEM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REMISSION; STRESS; THALAMUS MIDLINE NUCLEUS;

EID: 0042689390     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300257     Document Type: Article

References (55)

1. Aguilera G (1998). Corticotropin releasing hormone, receptor regulation and the stress response. Trends Endocrinol Metab 9: 329-336.
2. Altuvia S, Stein WD, Goldenberg S, Kane SE, Pastan I, Gottesman MM (1993). Targeted disruption of the mouse mdrlb gene reveals that steroid hormones enhance mdr gene expression. J Biol Chem 268: 27127-27132.
3. Barden N, Stec IS, Montkowski A, Holsboer F, Reul JM (1997). Endocrine profile and neuroendocrine challenge tests in transgenic mice expressing antisense RNA against the glucocorticoid receptor. Neuroendocrinology 66: 212-220.
4. Belanoff JK, Gross K, Yager A, Schatzberg AF (2001). Corticosteroids and cognition. J Psychiatr Res 35: 127-145.
5. Brunson KL, Avishai-Eliner S, Hatalski CG, Baram TZ (2001). Neurobiology of the stress response early in life: evolution of a concept and the role of corticotropin-releasing hormone. Mol Psychiatry 6: 647-656.
6. Cohen D, Piekarz RL, Hsu SI, DePinho RA, Carrasco N, Horwitz SB (1991). Structural and functional analysis of the mouse mdrlb gene promoter. J Biol Chem 266: 2239-2244.
7. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P et al (1989). The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 9: 1346-1350.
8. de Kloet ER, Vreugdenhil E, Oitzl MS, Joels M (1998). Brain corticosteroid receptor balance in health and disease. Endocrine Rev 19: 269-301.
9. Devault A, Gros P (1990). Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 10: 1652-1663.
10. Doze P, Van Waarde A, Elsinga PH, Hendrikse NH, Vaalburg W (2000). Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the blood-brain barrier. Synapse 36: 66-74.
11. Erkut ZA, Pool C, Swaab DF (1998). Glucocorticoids suppress corticotropin-releasing hormone and vasopressin expression in human hypothalamic neurons. J Clin Endocrinol Metab 83: 2066-2073.
12. Fink G, Robinson IC, Tannahill LA (1988). Effects of adrenalectomy and glucocorticoids on the peptides CRF-41, AVP and oxytocin in rat hypophysial portal blood. J Physiol 401: 329-345.
13. Gagner JP, Drouin J (1987). Tissue-specific regulation of pituitary proopiomelanocortin gene transcription by corticotropin-releasing hormone, 3′,5′-cyclic adenosine monophosphate, and glucocorticoids. Mol Endocrinol 1: 677-682.
14. Heuser I, Yassouridis A, Holsboer F (1994). The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 28: 341-356.
15. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A et al (2000). Functional polymorphism of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Acad Natl Sci USA 97: 3473-3478.
16. Holsboer F (1999). The rationale for the corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 33: 181-214.
17. Holsboer F (2000). The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23: 477-501.
18. Holsboer F, Barden N (1996). Antidepressants and hypothalamicpituitary- adrenocortical regulation. Endocrine Rev 17: 187-205.
19. Jin WD, Boutillier AL, Glucksman MJ, Salton SR, Loeffler JP, Roberts JL (1994). Characterization of a corticotropin-releasing hormone-responsive element in the rat proopiomelanocortin gene promoter and molecular cloning of its binding protein. Mol Endocrinol 8: 1377-1388.
20. Joels M (2001). Corticosteroid actions in the hippocampus. J Neuroendocrinol 13: 657-669.
21. Karssen AM, Meijer OC, van der Sandt ICJ, Lucassen PJ, de Lange EC, de Boer AG et al (2001). Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 142: 2686-2694.
22. Keck ME, Holsboer F (2001). Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders. Peptides 22: 835-844.
23. Korte SM (2001). Corticosteroids in relation to fear, anxiety and psychopathology. Neurosci Biobehav Rev 25: 117-142.
24. Kovács K (1998). Functional neuroanatomy of the parvocellular vasopressinergic system: transcriptional responses to stress and glucocorticoids. Progr Brain Res 119: 31-41.
25. Kwan P, Sills GJ, Butler E, Gant TW, Meldrum BS, Brodie MJ (2002). Regional expression of multidrug resistance genes in genetically epilepsy-prone rat brain after a single audiogenic seizure. Epilepsia 43: 1318-1323.
26. Lucassen PJ, Müller MB, Holsboer F, Bauer J, Holtrop A, Wouda J et al (2001). Hippocampal apoptosis in major depression is a minor event and absent from subareas at risk for glucocorticoid overexposure. Am J Pathol 158: 453-468.
27. Meaney MJ, Diorio J, Francis D, Widdowson J, LaPlante P, Caldji C et al (1996). Early environmental regulation of forebrain glucocorticoid receptor gene expression: implications for adrenocortical responses to stress. Dev Neurosci 18: 49-72.
28. Meijer OC, de Lange EC, Breimer DD, de Boer AG, Workel JO, de Kloet ER (1998). Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdrlA P-glycoprotein knockout mice. Endocrinology 139: 1789-1793.
29. Modell S, Yassouridis A, Huber J, Holsboer F (1997). Corticosteroid receptor function is decreased in depressed patients. Neuroendocrinology 65: 216-222.
30. Müller MB, Holsboer F, Keck ME (2002). Genetic modification of corticosteroid receptor signalling: novel insights into pathophysiology and treatment strategies of human affective disorders. Neuropeptides 17: 117-131.
31. Müller MB, Landgraf R, Sillaber I, Kresse AE, Keck ME, Zimmermann S et al (2000a). Selective activation of the hypothalamic vasopressinergic system in mice deficient for the corticotropin-releasing hormone receptor 1 is dependent on glucocorticoids. Endocrinology 141: 4262-4269.
32. Müller MB, Lucassen PJ, Hoogendijk WGJ, Holsboer F, Swaab DF (2001a). Neither major depression nor glucocorticoid treatment affects the cellular integrity of the human hippocampus. Eur J Neurosci 14: 1603-1612.
33. Müller MB, Preil J, Renner U, Zimmermann S, Kresse AE, Stalla GK et al (2001b). Expression of CRHR1 and CRHR2 in mouse pituitary and adrenal gland: implications for HPA system regulation. Endocrinology 142: 4150-4153.
34. Müller MB, Toschi N, Kresse AE, Post A, Keck ME (2000b). Long-term repetitive transcranial magnetic stimulation increases the expression of brain-derived neurotrophic factor and cholecystokinin mRNA, but not neuropeptide tyrosine mRNA in specific areas of rat brain. Neuropsychopharmacology 23: 405-415.
35. Owens MJ, Nemeroff CB (1991). Physiology and pharmacology of corticotropin releasing factor. Pharmacol Rev 43: 425-473.
36. Pariante CM, Hye A, Wiliamson R, Makoff A, Lovestone S, Kerwin RW (2003). The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology, advance online publication; doi: 10/1038/sj.npp.1300195.
37. Pariante CM, Miller AH (2001). Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 49: 391-404.
38. Pariante CM, Papadopoulus AS, Poon L, Chekley SA, English J, Kerwin RW et al (2002). A novel prednisolon suppression test for the hypothalamic- pituitary-adrenocortical axis. Biol Psychiatry 51: 922-930.
39. Raadsheer FC, Hoogendijk WJG, Stam FC, Tilders FJH, Swaab DF (1994). Increased number of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60: 436-444.
40. Raadsheer FC, van Heerikhuize JJ, Lucassen PJ, Hoogendijk WJG, Tilders FJH, Swaab DF (1995). Corticotropin-releasing hormone levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. Am J Psychiatry 152: 1372-1376.
41. Regina A, Koman A, Piciotti M, El Hafny B, Center MS, Bergmann R et al (1998). Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem 71: 705-715.
42. Sapolsky RM, Krey LC, McEwen BS (1985). Prolonged glucocorticoid exposure reduces hippocampal neuron number: implications for aging. J Neurosci 5: 1222-1227.
43. Schinkel AH (1998). Pharmacological insights from P-glycoprotein knockout mice. Int J Clin Pharmacol Therap 36: 9-13.
44. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ et al (1997). Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Acad Natl Sci USA 94: 4028-4033.
45. Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996). P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97: 2517-2524.
46. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P (1995). Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96: 1698-1705.
47. Seasholtz A, Bourbonais FJ, Harnden CE, Camper SA (1991). Nucleotide sequence and expression of the mouse corticotropin-releasing hormone gene. Mol Cell Neurosci 2: 266-273.
48. Tanimura SM, Watts AG (2001). Corticosterone modulation of ACTH secretagogue gene expression in the paraventricular nucleus. Peptides 22: 775-783.
49. Uhr M, Grauer MT, Holsboer F (2003). Differential enhancement of antidepressant penetration into the brain in mice with abcblab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry, in press.
50. Uhr M, Holsboer F, Müller MB (2002). Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J Neuroendocrinol 14: 753-759.
51. Uhr M, Sleekler T, Yassouridis A, Holsboer F (2000). Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdrla P-glycoprotein gene disruption. Neuropsychopharmacology 22: 380-387.
52. Uno H, Tarara R, Else JG, Suleman MA, Sapolsky RM (1989). Hippocampal damage associated with prolonged and fatal stress in primates. J Neurosci 9: 1705-1711.
53. Vale W, Spiess J, Rivier C, Rivier J (1981). Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science 213: 1394-1397.
54. van de Vrie W, Marquet RL, Stoter G, De Bruijn EA, Egggermont AM (1998). In vivo model systems in P-glycoprotein-mediated multidrug resistance. Crit Rev Clin Lab Sci 35: 1-57.
55. Wolf DC, Horwitz SB (1992). P-glycoprotein transports corticosterone and is photoaffinity-labeled by the steroid. Int J Cancer 52: 141-146.